Assessing the impact of FDG-PET in the management of anal cancer
| Autor: | Morikatsu Wada, Vincent Khoo, Michael Lim Joon, George Quong, Andrew See, Michael Chao, Andrew M. Scott, E. Zupan, M. Feigen, Daryl Lim Joon, K. Rykers, Cynleen Kai, B. Nguyen |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Disease Response Anal Carcinoma medicine.medical_treatment Fluorodeoxyglucose F18 Biopsy Carcinoma medicine Humans Anal cancer Radiology Nuclear Medicine and imaging Stage (cooking) Prospective cohort study Aged Aged 80 and over medicine.diagnostic_test business.industry Hematology Middle Aged Anus Neoplasms medicine.disease Radiation therapy Oncology Lymphatic Metastasis Positron-Emission Tomography Carcinoma Squamous Cell Female Radiology Radiopharmaceuticals business |
| Zdroj: | Radiotherapy and Oncology. 87:376-382 |
| ISSN: | 0167-8140 |
| DOI: | 10.1016/j.radonc.2008.04.003 |
| Popis: | Purpose To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease. Methods and materials Fifty histopathological anal cancer patients were reviewed between 1996 and 2006. The median age was 58 years (range 36-85) with 19 males:31females. Clinical assessment with CT was compared to PET. Impact on management, disease response, recurrence and metastases was evaluated. Results The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s. The primary was strongly FDG avid in 98% with non-excised tumors compared to CT (58%). PET upstaged 17% with unsuspected pelvic/inguinal nodal disease. Pre-treatment PET identified 11 additional by involved nodal groups in 48 patients causing RTP amendments in 19%. Post-treatment PETs at median 17 weeks (range 9–28) showed complete responses in 20 (80%) and 5 (20%) partial responses (PR). PRs were biopsy positive in 2 and negative in 3. Fifteen had follow-up scans of which all nine PETs detected recurrences were pathologically confirmed. Conclusions Anal cancer is FDG-PET avid. PET upstages 17% and changes the RTP in 19%. PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect